<b>Background:</b> Tumor necrosis factor-α (TNFα) inhibitors have significantly improved outcomes in children with non-systemic juvenile idiopathic arthritis (JIA), achieving long-term clinical remission for many patients. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.